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Abstract
Background: The ATM gene has been frequently involved in hereditary breast cancer as a low-
penetrance susceptibility gene but evidence regarding the role of ATM  as a breast cancer
susceptibility gene has been contradictory.
Methods: In this study, a full mutation analysis of the ATM gene was carried out in patients from
137 Chilean breast cancer families, of which 126 were BRCA1/2 negatives and 11 BRCA1/2 positives.
We further perform a case-control study between the subgroup of 126 cases BRCA1/2 negatives
and 200 controls for the 5557G>A missense variant and the IVS38-8T>C and the IVS24-9delT
polymorphisms.
Results:  In the full mutation analysis we detected two missense variants and eight intronic
polymorphisms. Carriers of the variant IVS24-9delT, or IVS38-8T>C, or 5557G>A showed an
increase in breast cancer risk. The higher significance was observed in the carriers of IVS38-8T>C
(OR = 3.09 [95%CI 1.11–8.59], p = 0.024). The IVS24-9 T/(-T), IVS38-8 T/C, 5557 G/A composite
genotype confered a 3.19 fold increase in breast cancer risk (OR = 3.19 [95%CI 1.16–8.89], p =
0.021). The haplotype estimation suggested a strong linkage disequilibrium between the three
markers (D' = 1). We detected only three haplotypes in the cases and control samples, some of
these may be founder haplotypes in the Chilean population.
Conclusion:  The IVS24-9 T/(-T), IVS38-8 T/C, 5557 G/A composite genotype alone or in
combination with certain genetic background and/or environmental factors, could modify the
cancer risk by increasing genetic inestability or by altering the effect of the normal DNA damage
response.
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Background
The incidence of breast cancer in Chile is still increasing
but the mortality rate in the last decade has remained con-
stant. Early detection contributes to mortality reduction
and genetic testing may identify high-risk individuals.
Mutations in BRCA1 and BRCA2 genes (BRCA1/2) have
been identified as high penetrance alleles. However, these
alleles explain only a small fraction of familial breast can-
cers [1,2]. We have previously screened for germ line
mutations in BRCA1/2, 64 Chilean families with several
cases of breast and/or ovarian cancer [3]. Only 15.6% of
these presented mutations in one of these two genes. The
most widely accepted model proposes that familial breast
cancer susceptibility is a consequence of a small number
of mutations in BRCA1/2 and a much larger variability in
ethnic-specific genes of moderate and/or low penetrance
[4]. The Ataxia-Telangiectasia Mutated gene (ATM) has
been frequently involved in hereditary breast cancer as a
low-penetrance susceptibility gene. The ATM kinase has
an essential role in maintaining genomic integrity. It is a
key activator of the cellular responses to DNA double-
strand breaks [5]. Individuals heterozygous for ATM
mutations have been reported to have an increased risk
for female breast cancer. A number of studies have
searched for germ line ATM mutations in breast cancer
cases and/or compared the frequency of common ATM
variants among breast cancer cases to population controls,
but evidence regarding the role of ATM as a breast cancer
susceptibility gene has been contradictory [6,7]. Recently,
large epidemiological and molecular studies have finally
provided conclusive evidence that ATM mutations that
cause ataxia-telangiectasia are breast cancer susceptibility
alleles [6,8]. There was no evidence that other classes of
ATM variants confer a risk of breast cancer [8]. A common
ATM variant IVS38-8T>C in cis with the 5557G>A ATM
variant, has been suggested to be associated with bilateral
breast cancer [9]. The 5557G>A variant has previously
been reported in the homozygous state to associate with
enhanced clinical radiosensitivity in breast cancer patients
[10-12].
In this study, we screened the entire coding region and
exon-intron boundaries of the ATM gene from 137 Chil-
ean familial breast cancer patients. We further evaluated
the 5557G>A missense variant and the IVS38-8T>C and
the IVS24-9delT polymorphisms, for breast cancer risk in
a subgroup of 126 familial breast cancer cases without
BRCA1/2 mutations and in 200 healthy controls.
Methods
Subjects
A total of 137 breast cancer patients (one case per family)
belonging to 137 high risk Chilean families were selected
from the files of the Metropolitan Santiago National
Health Service, National Cancer Society (Corporación
Nacional del Cancer -CONAC-) and the Arturo Lopez
Perez Foundation. Table 1 shows the specific characteris-
tics of the selected families according to the inclusion cri-
teria. All of the families participating in the study self
reported Chilean ancestry several generations ago, after
extensive interviews with several members of each family
pertaining to different generations. In the selected fami-
lies, 13.9% (19/137) presented cases of bilateral breast
cancer; and 7.3% (10/137) presented cases of both breast
and ovarian cancer. In the breast cancer group, the mean
age of diagnosis was 44,6 years and 67,9% had age onset
<50 years. Breast cancer was verified by the original
pathology report for all probands. The 137 index cases
(one case per family) were tested for BRCA1 and BRCA2
mutations as described elsewhere [3], of which 126 were
BRCA1/2 negatives and 11 BRCA1/2 positives.
Two hundred Chilean females used as controls were
recruited from the files of the CONAC, matched by age
and ethnic background with cases. Cases and controls
belonged to the same geographical area and the same
socioeconomic strata. Controls were interviewed and
informed as to the aims of the study. Control DNA sam-
ples were taken from unrelated individuals with no per-
sonal or familial history of breast or other cancer who
gave their consent for anonymous testing. Samples were
obtained under considerations of all ethical and legal
requirements.
This study was approved by the Institutional Review
Board of the School of Medicine of the University of
Chile. Informed consent was obtained from all the partic-
ipants.
Table 1: Selection criteria and clinical characteristics of the 
families included in this study.
Selection Criteria FAMILIES
2 family members with breast cancer 29
2 family members with breast cancer, onset before age 40 
in one
18
? 2 family members with breast cancer, bilateral in one 15
? 3 family members with breast cancer 32
? 3 family members with breast cancer, at least one with 
onset before age 40
26
3 family members with breast cancer, one male cancer 2
? 3 family members with a combination of breast and 
ovarian cancer
3
? 2 family members with breast cancer, one with both 
breast and ovarian cancer
2
Single affected individual with breast cancer < age 31 10
Breast cancer in male only 2
Total 137BMC Cancer 2008, 8:117 http://www.biomedcentral.com/1471-2407/8/117
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Mutation analysis
Genomic DNA of the 137 breast cancer cases was
extracted from peripheral blood lymphocytes obtained
according to the method described by Chomczynski and
Sacchi [13]. The whole coding sequence and exon-intron
boundaries of the ATM gene were amplified by polymer-
ase chain reaction (PCR). Primers were designed using
PRIMER3 software (See Additional file 1: Primers for ATM
mutation analysis and see Availability and requirements
for URL). The fragments obtained were analyzed for
sequence variants using conformational sensitive gel elec-
trophoresis (CSGE) [14]. Amplified samples were dena-
turated at 95°C for 5 minutes and 65°C for 30 minutes to
generate heteroduplex. The products were diluted 1:2 in
sucrose buffer and loaded in a partially denaturing MDE®
gel (Cambrex, UK) at constant power of 7 W during differ-
ent time periods depending on the size of the fragment.
Gels were silver-stained and dried on a vacuum gel dryer.
All sequence variants detected by CSGE were identified by
reamplification of the original DNA sample and direct
sequencing was performed in an ABI Prism 310 auto-
mated fluorescence-based cycle sequencer and a Rhodam-
ine dye terminator system (Perkin Elmer – Applied
Biosystems, Foster City, CA). The CSGE assay is techni-
cally simple and has a high sensitivity for the detection of
mutations. The main factors influencing sensitivity are the
gel matrix and the identity of base mismatch [15,16].
MDE matrix is a polyacrylamide-like matrix that has a
high sensitivity to DNA conformational differences. Sepa-
ration on a MDE gel provides superior results when com-
pared with standard polyacrilamide gels [17,18].
A polymerase chain reaction – restriction fragment length
polymorphism (PCR-RFLP) assay was used to genotype
IVS24-9delT, IVS38-8T>C and 5557G>A variants in the
subgroup of 126 cases BRCA1/2 negatives and in the 200
controls. PCR products were digested overnight with
restriction enzymes (New England Biolabs, MA, USA)
according to the manufacturer protocols and analyzed in
2% agarose gel electrophoresis. Primers, restriction
enzymes and the length of digested fragments are shown
in Table 2. Each sample of cases and controls for IVS24-
9delT, IVS38-8T>C and 5557G>A variants were amplified
and digested in two different occasions. We used PCR-
RFLP for genotyping IVS24-9delT, IVS38-8T>C and
5557G>A variants because CSGE only permits to detect
heterozygous. All the heterozygotes for each variant were
confirmed by sequencing and 100% concordance was
found between the RFLP and CSGE genotyping.
Statistical analysis
The Hardy-Weinberg equilibrium assumption was
assessed using standard maximum likelihood methods.
Fisher's exact-test was used to asses the association of alle-
les and/or genotypes between cases and controls, p < 0,05
was used as the criterion of significance. The odds ratio
(OR) and their 95% confidence interval (CI) were calcu-
lated to estimate the strength of the association between
cases and controls. Haplotype estimation was carried out
using UNPHASED software which uses a maximum like-
lihood approach [19].
Results
Table 3 shows the sequence variants found in the ATM
gene in the 137 patients. We detected two missense muta-
tions and eight intronic polymorphisms. The most fre-
quent variants were: IVS4+36insAA (46%); IVS48-
69insATT (50.5%); IVS24-9delT (20.6%) and 5557G>A
(20.6%). All the polymorphisms and the aminoacid sub-
stitutions detected in the present study have been previ-
ously described in different populations such as
Caucasians, Africans and Amerindians [20-22]. Of the
detected variants, eight were intronic polymorphisms, the
majority of which were located far of the donor or accep-
tor splice sites. Then, the probability that they represent
risk variants is very low. Thus, we considered not neces-
sary to study the frequency of the following variants in
controls: IVS4+36insAA, IVS17-56G>A, IV25-12insA,
IVS38-15G>C, IVS47-65G>C, and IVS48-69insATT.
In the current investigation, we performed a case-control
study between the subgroup of 126 cases BRCA1/2 nega-
tive and 200 controls, for the 5557G>A missense variant
and for the IVS38-8T>C and IVS24-9delT polymorphisms.
Heikkinen et al. [9] proposed a cancer risk-modifying
effect for the ATM 5557G>A – IVS38-8 T>C composite
allele. The IVS24-9delT was studied because it is located in
the acceptor splice site of intron 24 and for its higher fre-
quency in cases. We analyzed the allelic, genotype and
composite genotype frequencies for the variants men-
Table 2: Primers, restriction enzymes and fragment lengths for IVS24-9delT, 5557G>A and IVS38-8T>C variants
Variant Primer secuence (1) Anealing temperature Restriction enzyme Fragment lengths
IVS24-9delT F 5' ACTAAGCTGCTGGTCTGAAC 3' R 5' 
GTCCTGGAACAATCTTAAAGC 3'
48°C FnuH I T allele : 176 bp + 24 bp (-T) allele: 199 bp
IVS38-8T>C F 5' ATGGTAATGGCCTAGACTGG 3' R 5' 
ATCCAAGTTTGCAGGGGTTG 3'
58°C Rsa I T allele: 295 bp + 148 bp C allele: 260 bp + 
148 bp + 35 bp
5557G>A F 5' TAATATGTCAACGGGGCATG 3' R 5' 
ATTTCTCCATGATTCATTTGGAT 3'
52°C Rsa I G allele: 156 bp + 23 bp A allele: 179 bp
(1) Underlined base indicates a mismatch to create the restriction siteBMC Cancer 2008, 8:117 http://www.biomedcentral.com/1471-2407/8/117
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tioned above and compared them with controls. These
variants were in Hardy-Weinberg equilibrium in the stud-
ied groups. The frequency of 5557A allele (allele analysis)
was 0.10 in BRCA1/2 negative cases versus 0,06 in con-
trols (p = 0,056, OR = 1.67 [95% CI 0.94–2.92]). Never-
theless, the frequency of 5557A allele carriers (genotype
analysis) was 0.21 in cases versus 0.13 in controls (p =
0.048, OR = 1.74 [95%CI 0.96–3.16]) (Table 4). Similar
results were observed for the allelic and genotype frequen-
cies of the IVS24-9delT polymorphism (Table 4). With
respect to IVS38-8T>C polymorphism, the IVS38-8C
allele frequency was higher in BRCA1/2  negative cases
(0.05) than in healthy controls (0.01) and the difference
was significant (p = 0.025, OR = 3.00 [95%CI 1.09–8.21])
(Table 4). Moreover, we observed a higher frequency of
IVS38-8C allele carriers in cases versus controls, being the
difference statistically significant (p = 0.024, OR = 3.09
[95%CI 1.11–8.59]). Therefore, each of the genotypes
may confer an increase in breast cancer risk. Nevertheless
the higher significance was observed in the carriers of the
IVS38-8T>C. With respect to the 11 BRCA1/2  positive
index cases, none of them carried the analyzed variants.
Table 3: ATM variants found in familial breast cancer cases.
Intron/exon Variant HUGO (1) nomenclature rsID (2) Effect Heterozygous frecuency Heterozygous frecuency 
dbSNP database
Described by
4 IVS4+36insAA c.72+36insAA rs2066734 Unknown 46,0% 41.9% (3) [20]
6 378T>A c.378T>A rs2234997 p.D126E 0,8% 8.7% (4) [22]
17 IVS17-56G>A c.2377-56G>A rs672655 Unknown 46,8% 43.6% (3) [20]
24 IVS24-9delT c.3249-9delT rs3218698 Unknown 20,6% 13,3% (5) [20]
25 IVS25-12insA c.3366-12insA rs4987984 Unknown 49,2% 48.2% (3) [22]
38 IVS38-15G>C c.5320-15G>C rs3092828 Unknown 0,8% 1.0% (6) [22]
38 IVS38-8T>C c.5320-8T>C rs3092829 Unknown 8,7% 4,5% (4) [20]
38 5557G>A c.5557G>A rs1801516 p.D1853N 20,6% 10,3% (5) [20]
47 IVS47-65G>C c.6516-65G>C rs4988104 Unknown 1,7% 2.4% (7) -
48 IVS48-69insATT c.6751-69insATT rs3212322 Unknown 49,2% 43.2% (3) [21]
(1) HUGO: Human Genome Organization.
(2) rs numbers are from human single nucleotide polimorphisms database (dbSNP) http://www.ncbi.nlm.nih.gov/SNP
(3) Estimated frequency in NCBI:NIHPDR sample (90 individuals from North American population). http://www.ncbi.nlm.nih.gov/SNP/snp_ss.cgi?ss=ss4479871.
(4) Estimated frequency in SNP500CANCER:HISP1 sample (23 individuals from Hispanic population). http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?pop=777.
(5) Estimated frequency in NIHPDR sample (450 unselected for ethnicity) http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?pop=506.
(6) Estimated frequency in OEFNER:autosome sample (97 individual unselected for ethnicity). http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?pop=527.
(7) Estimated frequency in EGP_SNPS:PDR90 sample (90 individual unselected for ethnicity). http://www.ncbi.nlm.nih.gov/SNP/snp_viewTable.cgi?pop=693.
Table 4: Genotype and allele frequencies of IVS24-9delT, IVS38-8T>C and 5557G>A ATM variants in BRCA1/2 negative breast cancer 
cases and controls.
ATM variant BC cases (%) (n = 126) Controls (%) (n = 200) p value (a) OR [95%CI]
IVS24-9delT
T/T 100 (79.4%) 174 (87.0%) 1.000 1.00
T/(-T) 26 (20.6%) 26 (13.0%) 0.048 1.74 [0.96–3.16]
(-T)/(-T) 0 (0%) 0 (0%) - -
T allele 226 (0.90) 374 (0.94) 1.00 1.00
(-T) allele 26 (0.10) 26 (0.06) 0.056 1.67 [0.94–2.92]
IVS38-8T>C
T/T 115 (91.3%) 194 (97.0%) 1.000 1.00
T/C 11 (8.7%) 6 (3.0%) 0.024 3.09 [1.11–8.59]
C/C 0 (0%) 0 (0%) - -
T allele 241 (0.95) 394 (0.99) 1.000 1.00
C allele 11 (0.05) 6 (0.01) 0.025 3.00 [1.09–8.21]
5557G>A
G/G 100 (79.4%) 174 (87.0%) 1.000 1.00
G/A 26 (20.6%) 26 (13.0%) 0.048 1.74 [0.96–3.16]
A/A 0 (0%) 0 (0%) - -
G allele 226 (0.90) 374 (0.94) 1.000 1.00
A allele 26 (0.10) 26 (0.06) 0.056 1.67 [0.94–2.92]
BC: breast cancer.
(a) Fisher exact test.BMC Cancer 2008, 8:117 http://www.biomedcentral.com/1471-2407/8/117
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Table 5 shows the composite genotype analysis for IVS24-
9delT, IVS38-8T>C and 5557G>A. In accordance with the
findings of Heikkinen et al. [9] and Langholz et al. [23],
we also observed that IVS38-8T>C carriers were also carri-
ers for 5557G>A in BRCA1/2 negative cases and controls.
The IVS24-9 T/(-T), IVS38-8 T/C, 5557 G/A composite
genotype showed a higher frequency in cases (8,7%) com-
pared to controls (3.0%) (p = 0.021, OR = 3.19 [95%CI
1.16–8.89]) (Table 5). Thus, this composite genotype
confers a 3.19 fold increase in breast cancer risk. In addi-
tion, the frequency of T/(-T), T/T, G/A composite geno-
type did not differ between BRCA1/2  negative cases
(11.9%) versus controls (10.0%) (p = 0.289, OR = 1.31
[95%CI 0.63–2.66]). Table 5 also shows that the analyzed
variants are highly correlated in relation to the risk for
breast cancer. All the IVS38-8T>C heterozygotes were also
IVS24-9delT and 5557G>A heterozygotes, both in cases
(11/126) and controls (6/200). The difference is given by
IVS24-9delT heterozygotes that are also associated to
IVS38-8 T/T (15/126 in cases and 20/200 in controls), but
not to 5557 G/G (0/126 cases, 0/200 controls), and
5557G>A heterozygotes that are not associated to IVS24-
9 T/T (0/126 cases, 0/200 controls), and are associated to
IVS38-8 T/T (15/126 cases, 20/200 controls). This fact
raises the possibility for these variants to be in strong link-
age disequilibrium.
Although phase for alleles at these 3 variants could not be
determined directly from the screening data, haplotypes
where constructed from genotype data using UNPHASED
software, which uses a maximum-likelihood aproach. The
total number of haplotypes with the three markers are
eight, but in the cases and controls we observed only three
which correspond to wildtype (IVS24-9 T – IVS38-8 T –
5557 G); IVS24-9 (-T) – IVS38-8 T – 5557 A; and IVS24-9
(-T) – IVS38-8 C – 5557 A haplotypes. The haplotype esti-
mation suggested a strong linkage disequilibrium
between the three markers (coefficient of linkage disequi-
librium, D' = 1), a result which had previously been sug-
gested by composite genotype analysis.
Discussion
Heterozygous individuals for germline ATM  mutations
have been reported to have an increased risk for malig-
nancy, in particular, female breast cancer. In this study we
detected a low ATM diversity in breast cancer women, and
this variation was minor in the coding region with respect
to noncoding regions. This result is in accordance to
Thorterson et al. [22], which established that the nucle-
otide diversity of ATM  in the coding and non coding
region have a ratio of 1:7.5, probably due to selective pres-
sure for maintaining the protein sequence. The ATM vari-
ations in this study were also minor with respect to those
informed by Tapia et al. [24]in Chilean women with
Table 5: Composite genotype frequencies for IVS24-9delT, IVS38-8T>C and 5557G>A ATM variants in BRCA1/2 negative breast cancer 
cases and controls.
Composite genotype BC cases (n = 126) Controls (n = 200) p value (a) OR [95%CI]
IVS24-9delT, IVS38-8T>C
T/T, T/T 100 (79.4%) 174 (87.0%) 1.000 1.00
T/(-T), T/T 15 (11.9%) 20 (10.0%) 0.289 1.31 [0.63–2.66]
T/(-T), T/C 11 (8.7%) 6 (3.0%) 0.021 3.19 [1.16–8.89]
IVS38-8T>C, 5557G>A
T/T, G/G 100 (79.4%) 174 (87.0%) 1.000 1.00
T/T, G/A 15 (11.9%) 20 (10.0%) 0.289 1.31 [0.63–2.66]
T/C, G/A 11 (8.7%) 6 (3.0%) 0.021 3.19 [1.16–8.89]
IVS24-9delT, 5557G>A
T/T, G/G 100 (79.4%) 174 (87.0%) 1.000 1.00
T/(-T), G/A 26 (20.6%) 26 (13.0%) 0.048 1.74 [0.96–3.16]
IVS24-9delT, IVS38-8T>C, 5557G>A
T/T, T/T, G/G 100 (79.4%) 174 (87.0%) 1.000 1.00
T/(-T), T/T, G/A 15 (11.9%) 20 (10.0%) 0.289 1.31 [0.63–2.66]
T(/-T), T/C, G/A 11 (8.7%) 6 (3.0%) 0.021 3.19 [1.16–8.89]
BC: breast cancer.
(a) Fisher exact test.BMC Cancer 2008, 8:117 http://www.biomedcentral.com/1471-2407/8/117
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hereditary breast cancer. Probably, this may be due to the
ethnic origin of the families included. In Tapia et al. study
[24], 28% of the families were of European ancestry, prob-
ably biasing the results of this study. In our study, all of
the families were of Chilean ancestry several generations
ago.
In the present study all the polymorphisms and the ami-
noacid substitutions detected have been previously
described in other populations of different ethnic origins,
including the ATM  missense variant 5557G>A and the
IVS24-9delT and IVS38-8T>C polymorphisms.
Some previous studies have proposed a phenotypic effect
for the common ATM  missense variation 5557G>A in
exon 39 [10-12]. Heikkinen et al. [9], in their mutation
analysis of the ATM gene in patients from 121 Northern
Finnish breast or breast-ovarian cancer families reported
that the haplotype composed of the alleles 5557A and
IVS38-8C was significantly associated with bilateral breast
cancer. In a later report, Langholz et al. [23] in the
WECARE Study population did not find that the haplo-
type of 5557G>A and IVS38-8T>C confered an increased
risk to women with bilateral breast cancer when com-
pared with women with unilateral breast cancer. Never-
theless, the WECARE Study is population-based and
unselected for family history. Tommiska et al. [25] evalu-
ated the 5557G>A and IVS38-8T>C variants in an exten-
sive analysis that included familial breast cancer cases and
healthy controls of Southern Finland. In their study nei-
ther 5557G>A nor IVS38-8T>C or any haplotype contain-
ing these variants, was associated with breast cancer risk or
bilateral cancer, but in familial breast cancer cases there
was a higher frequency of IVS38-8T>C carriers than in
controls (8.1% and 5.6%, respectively). Tapia et al. [24] in
a study in Chilean women with hereditary breast cancer
found a positive association of 5557G>A (OR = 2.52, p =
0.008), when analyzed alone and in combination with
the IVS24-9delT intronic variant (OR = 3.97, p = 0.0003).
In our case-control study of the IVS38-8T>C, 5557G>A
and IVS24-9delT variants, the frequency of IVS38-8C
allele was higher in BRCA1/2 negative cases (0.05) than in
controls (0.01) and the difference was significant (p =
0.025, OR = 3.00 [95%CI 1.09–8.21]) (Table 4). The data-
base (dbSNP rs3092829) reported for IVS38-8C allele fre-
quencies of 0.023 in the Hispanic population, 0.016 in
Caucasians and 0.01 in Europeans which are in accord-
ance with those of our control group. The frequency of the
5557A allele in controls is also similar to those published
in the database (dbSNP rs1801516). Our results with
respect to IVS38-8T>C and 5557G>A allele control fre-
quencies differ from those reported by Tapia et al. [24],
which selected the control sample from a blood bank of
Santiago, Chile. In our study controls were interviewed,
age matched with cases, and correspond to individuals
with no personal or familial history of breast and other
cancer. Cases and controls were from the same ethnic
group, and from the same geographic area. The major
problem in case-control studies is ensuring a good match
between their genetic background, so that any genetic dif-
ference between them is related to the disease under study
and not to biased sampling [26]. This may be the reason
why in the Tapia et al. study [24] controls showed no sig-
nificant differences with cases in the allele frequencies of
these markers.
In our study the carriers of the variant IVS24-9delT, or
IVS38-8T>A, or 5557G>A (genotype frequencies) showed
an increase in breast cancer risk, although the statistical
significance was higher for the variant IVS38-8T>C (OR =
3.09 [95%CI 1.11–8.59] p = 0.024) (Table 4).
We also analyzed the effect of the composite genotypes in
breast cancer risk. In accordance with the findings of Heik-
kinen et al. [9] and Tommiska et al. [25] in the Finnish
population, and Langholz et al. [23] in the WECARE sam-
ple, we observed that all the carriers of IVS38-8C allele
were also carriers of 5557A allele. Then, it is possible that
IVS38-8T>C occurs in combination with 5557G>A. We
observed, both in cases and controls, only three of the 27
possible composite genotypes, and of these the trihetero-
zygote composite genotype showed a higher frequency in
cases (8.7%) than controls (3.0%), being the difference
statistically significant (OR = 3.19 [95%CI 1.16–8.89], p
= 0.021) conferring an increased risk among women with
familial breast cancer. The composite genotype T/(-T), T/
T, G/A presented a similar frequency in cases (11.9%) and
in controls (10.0%) (Table 5). In agreement with Heik-
kinen's report [9], our results could indicate that the het-
erozygous condition for IVS38-8T>C and 5557G>A may
be responsible of the association between T/(-T), T/C, G/
A composite genotype and an increased risk of familial
breast cancer. Nevertheless, we cannot rule out the possi-
bility that T/(-T), T/C, G/A constitutes a risk composite
genotype. Another possibility is that this composite geno-
type in combination with certain genetic background
and/or environmental factors, could modify the cancer
risk by increasing genetic inestability or by altering the
effect of the normal DNA damage response. The present
observations need to be confirmed by additional case-
control and functional studies.
We observed a strong linkage disequilibrium between the
three analyzed markers. Therefore, of the three haplotypes
detected in the cases and control samples some of theese
may be founder haplotypes, given that the contemporary
Chilean population stems from the admixture of Amerin-
dian peoples with the Spanish settlers (European Cauca-
sian). The relationship between ethnicity, Amerindian
admixture, genetic markers, and socioeconomic strata hasBMC Cancer 2008, 8:117 http://www.biomedcentral.com/1471-2407/8/117
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been extensively studied in Chile [27-29]. Moreover, it has
been reported a low prevalence of breast cancer in those
regions of the country where the Amerindian population
is concentrated and represents demographically a sub-
stancial proportion of the people of such regions.
With the exception of the studies performed in Northern
and Southern Finnish populations, there are no reports
for other European populations were the association
between familial breast cancer with the IVS24-9delT,
IVS38-8T>C and 5557G>A variants has been analyzed.
Therefore, probably the association reported in our study
may also exist in other populations with a different ethnic
background, such as other European, Asian or Amerin-
dian populations.
With respect to the Amerindian populations a consensus
among anthropologists was reached in the sense that
Amerindians derived from Asians which, moving from
Asia, crossed the Bering Land Bridge [30]. Then, we also
raise the hypothesis that the haplotype IVS24-9(-T) –
IVS38-8C – 5557A may be a risk haplotype in some con-
temporary South American populations that stem from
the admixture of Amerindian peoples with the Spanish
settlers. Up to date, there are no reports of these variants
in Asian and Spanish populations.
Conclusion
The findings of our study were: a) we determined that the
BRCA1/2 negatives cancer patients that were carriers of the
IVS24-9delT, IVS38-8T>C or 5557G>A showed an
increase in brest cancer risk; b) we observed that all the
carriers of IVS38-8C allele were also carriers of IVS24-
9delT and 5557A alleles, a finding which suggests that
IVS38-8T>C occurs in combination with the latter vari-
ants; and c) we established that the IVS24-9 T/(-T), IVS38-
8 T/C, 5557G/A composite genotype confers a 3,19 fold
increase in breast cancer. The most important finding and
contributions of this study is that a triheterozygous com-
posite genotype confers an increase in the risk for breast
cancer. Probably this composite genotype exists in the
structure of the Chilean population which may also exists
in other South American poulations.
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